Search research articles
Contact Us
Filters
Showing results (91-100 of 126) with videos related to
Page
of 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
October 12, 2023
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma
Rachel S Goodman, Lorenza Di Guardo, Andrea Maurichi, et al.
Molecular Cancer Research : MCR
|
April 3, 2021
Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients
Lauren G Aoude, Bernadette Z Y Wong, Vanessa F Bonazzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Jayesh Desai, Hui Gan, Catherine Barrow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Timothy A Yap, Maria Vieito, Capucine Baldini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Georgina V Long, James Larkin, Dirk Schadendorf, et al.
The Lancet. Oncology
|
July 22, 2017
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
Georgina V Long, Victoria Atkinson, Jonathan S Cebon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2025
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Adi Diab, Paolo A Ascierto, Michele Maio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
Martin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Adi Diab, Paolo A Ascierto, Michele Maio, et al.
JAMA Oncology
|
November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A Ascierto, Georgina V Long, Caroline Robert, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 126) with videos related to
Sort By:
Page
of 13
European Journal of Cancer (Oxford, England : 1990)
|
October 12, 2023
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma
Rachel S Goodman, Lorenza Di Guardo, Andrea Maurichi, et al.
Molecular Cancer Research : MCR
|
April 3, 2021
Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients
Lauren G Aoude, Bernadette Z Y Wong, Vanessa F Bonazzi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Jayesh Desai, Hui Gan, Catherine Barrow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Timothy A Yap, Maria Vieito, Capucine Baldini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Georgina V Long, James Larkin, Dirk Schadendorf, et al.
The Lancet. Oncology
|
July 22, 2017
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
Georgina V Long, Victoria Atkinson, Jonathan S Cebon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2025
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Adi Diab, Paolo A Ascierto, Michele Maio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection
Martin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Adi Diab, Paolo A Ascierto, Michele Maio, et al.
JAMA Oncology
|
November 14, 2018
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A Ascierto, Georgina V Long, Caroline Robert, et al.
Page
of 13